High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes

Leuk Res. 2011 Jun;35(6):766-70. doi: 10.1016/j.leukres.2011.01.009. Epub 2011 Mar 1.

Abstract

Expression of CD34 on mature-appearing megakaryocytes can be seen in various intrinsic bone marrow (BM) disorders as well as reactive bone marrows. In this study we investigate the clinical significance of CD34+ megakaryocytes in myelodysplastic syndromes (MDSs). Expression of CD34 on megakaryocytes was assessed on BM biopsies obtained from 202 patients with MDS. High-level (≥20%) CD34 expression on megakaryocytes was found in BM of 29 patients (14%). The expression of CD34 on megakaryocytes is correlated with severe cytopenia, higher numbers of myeloblasts, more frequent and higher risk cytogenetic abnormalities, and a shorter overall survival. Multivariate analysis indicated that the expression of CD34 on megakaryocytes could be a strong and an independent poor prognostic factor in MDS, with a hazard ratio of 2.53.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD34 / biosynthesis*
  • Biopsy
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Megakaryocytes / metabolism*
  • Megakaryocytes / pathology
  • Middle Aged
  • Multivariate Analysis
  • Myelodysplastic Syndromes / metabolism*
  • Myelodysplastic Syndromes / pathology
  • Outcome Assessment, Health Care / methods
  • Outcome Assessment, Health Care / statistics & numerical data
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models

Substances

  • Antigens, CD34